All In Biotech

Drug Trial Radar · NCT05634811

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY OF A 6-VALENT OspA-BASED LYME DISEASE VACCINE (VLA15) IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE

Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,547 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,547

Actual

Start

Dec 12, 2022

Primary completion

Jul 21, 2025

Study completion Jul 21, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to understand if the study vaccine (called VLA15) is safe in healthy children. We are looking for children who: * are healthy * are age 5 through 17 * have not been diagnosed with any form of Lyme disease in the past * have not received any vaccines for Lyme disease in the past Lyme disease happens most often in children of this age. The study vaccine may be used potentially to help prevent Lyme disease. The goal of this study is to get more information about the safety of the study vaccine in this age group. Participants will be in this study for about 2 years. During that time, they will receive VLA15 or placebo (sterile saltwater solution) by a "shot" in the arm. We will compare experience of children receiving VLA15 to those receiving the placebo. Participants will not know whether they get VLA15 or placebo. Everyone participating in this study will: * get the shots in a clinic or in a hospital office * receive a total of 4 shots * receive the first 3 shots within 6 months * receive the last shot about 1 year afterwards * need to come to the trial site for 6 planned visits; 4 of these are vaccination visits and 2 are follow-up visits. We will contact you by phone 1 time every year during the study to monitor your experience. You may have extra visits if you experience a severe reaction after a vaccine dose.

Conditions

  • Lyme Disease

Interventions

  • VLA15Biological

    6-valent OspA-based Lyme disease vaccine

  • Normal SalineOther

    0.9% sodium chloride solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 1Time frame: From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)
  2. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 2Time frame: From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)
  3. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 3Time frame: From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)
  4. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)Time frame: From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)
  5. Percentage of Participants With at Least 1 Local Reaction of Any Grade for up to 7 Days After Any Study VaccinationTime frame: From Day 1 through Day 7 after any study vaccination
  6. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 1Time frame: From Day 1 through Day 7 after Study Vaccination 1 (Vaccination on Day 1, Month 0)
  7. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 2Time frame: From Day 1 through Day 7 after Study Vaccination 2 (Vaccination on Day 1, Month 2)
  8. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 3Time frame: From Day 1 through Day 7 after Study Vaccination 3 (Vaccination on Day 1, Month 6)
  9. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days Following Study Vaccination 4 (Booster Dose)Time frame: From Day 1 through Day 7 after Study Vaccination 4 (Vaccination on Day 1, Month 18)
  10. Percentage of Participants With at Least 1 Systemic Event of Any Grade for up to 7 Days After Any Study VaccinationTime frame: From Day 1 through Day 7 after any study vaccination
  11. Percentage of Participants With AEs Through 1 Month Following Study Vaccination 1Time frame: From Day 1 through 1 Month after Study Vaccination 1 (Vaccination on Day 1, Month 0)
  12. Percentage of Participants With AEs Through 1 Month Following Study Vaccination 2Time frame: From Day 1 through 1 Month after Study Vaccination 2 (Vaccination on Day 1, Month 2)
  13. Percentage of Participants With AEs Through 1 Month Following Study Vaccination 3Time frame: From Day 1 through 1 Month after Study Vaccination 3 (Vaccination on Day 1, Month 6)
  14. Percentage of Participants With AEs Through 1 Month Following Study Vaccination 4 (Booster Dose)Time frame: From Day 1 through 1 Month after Study Vaccination 4 (Vaccination on Day 1, Month 18)
  15. Percentage of Participants With AEs Through 1 Month Following Any Study VaccinationTime frame: From Day 1 through 1 Month after any study vaccination
  16. Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMCs) Throughout the StudyTime frame: Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)
  17. Percentage of Participants With Serious Adverse Events (SAEs) Throughout the StudyTime frame: Throughout the study (from study vaccination 1 through 6 months post study Vaccination 4 [Booster dose]: maximum up to 24 months)

Locations

65 sites in 1 country. Site status is shown where the registry gives one.

  • UAB Child Health Research Unit (CHRU)

    Birmingham, Alabama

  • University of Alabama at Birmingham - School of Medicine

    Birmingham, Alabama

  • Lakeview Clinical Research

    Guntersville, Alabama

  • Coast Clinical Research, LLC

    Bellflower, California

  • Apex Research Group LLC

    Fair Oaks, California

  • New England Research Associates

    Bridgeport, Connecticut

  • Stamford Therapeutics Consortium

    Stamford, Connecticut

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Bio-Medical Research LLC

    Miami, Florida

  • GCP Research, Global Clinical professionals

    St. Petersburg, Florida

  • MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research

    Tampa, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Tekton Research, LLC.

    Chamblee, Georgia

  • ASR, LLC

    Boise, Idaho

  • Clinical Research Prime

    Idaho Falls, Idaho

  • Clinical Research Prime Rexburg

    Rexburg, Idaho

  • University of Chicago Medical Center

    Chicago, Illinois

  • AMR Clinical

    El Dorado, Kansas

  • AMR Clinical

    Wichita, Kansas

  • Kentucky Pediatric/ Adult Research

    Bardstown, Kentucky

  • All Children Pediatrics

    Louisville, Kentucky

  • MD Medical Research

    Oxon Hill, Maryland

  • White Oak Pediatrics

    Silver Spring, Maryland

  • Sisu BHR

    Springfield, Massachusetts

  • Michigan Center of Medical Research (MICHMER)

    Bingham Farms, Michigan

  • Vida Clinical Studies, LLC

    Dearborn Heights, Michigan

  • Great Lakes Research Institute

    Southfield, Michigan

  • Clinical Research Institute

    Minneapolis, Minnesota

  • Velocity Clinical Research, Omaha

    Omaha, Nebraska

  • Hassman Research Institute

    Marlton, New Jersey

  • Rutgers University

    New Brunswick, New Jersey

  • IMA Clinical Research Warren

    Warren Township, New Jersey

  • Velocity Clinical Research, Binghamton

    Binghamton, New York

  • Buffalo Clinical and Translational Research Center

    Buffalo, New York

  • Advanced Specialty Care

    Commack, New York

  • Smith Allergy and Asthma Specialists

    Cortland, New York

  • Stony Brook Medicine Clinical Research Center

    East Setauket, New York

  • Upstate Global Health Institute

    East Syracuse, New York

  • Southampton Hospital

    Hampton Bays, New York

  • Smith Allergy & Asthma Specialists

    Horseheads, New York

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.